New trials for prostate cancer
Enzalutamide for prostate cancer
ANZUP and the CTC are collaborating with
research groups around the world to conduct two of the largest
clinical trials for sufferers of the world's most commonly
diagnosed form of cancer, prostate cancer. The trials, ENZAMET and
ENZARAD, aim to recruit 1900 men with prostate cancer in Australia,
New Zealand, USA, Canada, UK, and Ireland.
Professor Ian Davis, Chair of ANZUP and Lead
Investigator for the new global trials recently stated in the media
"the trials may provide opportunities to
change the lives of prostate cancer sufferers around the
"These two trials aim to answer the basic
questions that patients and their doctors face every day in the
clinic: what is the best way of treating men with prostate
"They will be two of the largest trials in
prostate cancer and people around the world are already intensely
interested in them and what their outcomes might be. These trials
demonstrate once again that Australia punches above its weight in
They involve a new hormone treatment,
Enzalutamide, which is not currently approved in Australia for use
in prostate cancer but has been shown to be effective in treating
late stages of the disease.
The ENZAMET trial will involve about 1100 men
with prostate cancer that has spread but has not yet been treated
The ENZARAD trial will include about 800 men
with prostate cancer that has not spread and that is planned for
treatment with radiotherapy.
Astellas Scientific and Medical Affairs Inc. are providing
Enzalutamide and financial support. The ENZAMET and
ENZARAD trials are investigator-initiated and we encourage men
with prostate cancer to seek further information from their general
Read more about ENZARAD here. Read more about ENZAMET here.